

No increase in acute kidney injury risk for SGLT2 users

24 August 2017



respectively, had an AKI_{KDIGO} event. The unadjusted hazards of AKI_{KDIGO} were lower in users (HR, 0.5; 95 percent CI, 0.3 to 0.8; P

"Our findings do not suggest an increased risk of AKI associated with SGLT2 inhibitor use in patients with type 2 diabetes in two large health systems," the authors write.

More information: [Abstract/Full Text](#) (subscription or payment may be required)

Copyright © 2017 [HealthDay](#). All rights reserved.

(HealthDay)—The risk of acute kidney injury (AKI) is not increased for new sodium-glucose cotransporter-2 (SGLT2) inhibitor users, according to a study published online Aug. 21 in *Diabetes Care*.

Girish N. Nadkarni, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues assessed the real-world risk of AKI using data for 377 SGLT2 inhibitor users and 377 nonusers in the Mount Sinai chronic kidney disease registry and for 1,207 users and 1,207 nonusers in the Geisinger Health System cohort.

The researchers found that over a median follow-up of 14 months, 3.8 and 9.7 percent of SGLT2 users and nonusers in the Mount Sinai cohort, respectively, had an AKI_{KDIGO} event (hazard ratio [HR], 0.4; 95 percent confidence interval [CI], 0.2 to 0.7; P = 0.01); the HR was unchanged after adjustment (adjusted HR, 0.4; 95 percent CI, 0.2 to 0.7; P = 0.004). Within the Geisinger cohort, 2.2 and 4.6 percent of users and nonusers,

APA citation: No increase in acute kidney injury risk for SGLT2 users (2017, August 24) retrieved 15 April 2021 from <https://medicalxpress.com/news/2017-08-acute-kidney-injury-sglit2-users.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.